TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice

The authors identified a metabolite produced by intestinal bacteria, TMAVA, that worsens fatty liver disease by reducing production of the amino acid carnitine. Carnitine might therefore be used for treatment of fatty liver.

Source link

Related posts

Liver Diseases and Causes


Signs That You May Have Acid Reflux


Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy